JPRN-UMIN000031028招募中2 期
A phase II trial of FOLFOXIRI+Bevacizumab as preoperative chemotherapy for locally advanced lower rectal cancer - A phase II trial of FOLFOXIRI+Bev as preoperative chemotherapy for lower rectal cancer
Kobe University Graduate School of Medicine0 个研究点目标入组 40 人开始时间: 2018年4月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Previously treated with systemic chemotherapy, radiotherapy, hormone therapy, or immunotherapy for the present disease 2. Severe drug intorelance 3. Peripheral neuropathy (>= Grade 1) 4. Infectious disease to be treated 5. Uncontrollable hypertension 6. Uncontrollable diabetes mellitus 7. Severe heart disease such as congestive heart failure, pectoris, and myocardial infarction. 8. Severe pulmonary disease 9. Severe mental disease 10. Active bleeding from the intestine 11. Currently treated by Phenytoin, Warfarin, or Flucytosine. 12. Diarrhea(>= Grade 2) 13. Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ or mucosal carcinoma 14. Women during pregnancy, possible pregnancy or breast-feeding 15. Liver chirrhosis or hepatitis 16. UGT1A1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 17. Attending physician determines that the case was inappropriate as the subject of this study
研究者
相似试验
已完成
2 期
Phase II trial of FOLFOXIRI + Bevacizumab in patients with untreated metastatic colorectal cancerPatients with metastatic colorectal cancerJPRN-UMIN000017102Translational Research Informatics Center, Foundation for Biomedical Research and Innovation45
已完成
2 期
Phase II trial of FOLFIRI plus Bevacizumab in second-line therapy after progression on bevacizumab with oxaliplatine-based chemotherapy in patients with metastatic colorectal cancer whose KRAS status are investigated.Recurrent or metastatic colorectal cancerJPRN-UMIN000004219Hyogo Cancer Center, Dept. of Gastrointestinal and Hepatobiliary Oncology40
进行中（未招募）
不适用
Phase II trial FOLFOX combined with Bevacizumab, Cetuximab and Imatinib in patients with advanced untreated colorectal cancer - NDEUCTR2006-001779-39-ITAzienda Ospedaliera Universitaria S.Martino - U.O. Oncologia Medica - Genova
进行中（未招募）
不适用
Marker Evaluation for Avastin Research in colorectal cancerEUCTR2011-004755-39-EEGenentech, Inc.360
进行中（未招募）
1 期
Marker Evaluation for Avastin Research in colorectal cancerMetastatic colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2011-004755-39-IEGenentech, Inc.360